Scanbo: Scaling AI Diagnostics with Ethical Innovation
October 23, 2026 | Friday | Features
A connected point-of-care diagnostic platform that combines portable medical devices, artificial intelligence and digital health data to support faster clinical decisions. Founded by Ashissh Raichura, the company operates internationally, with manufacturing and R&D in Surat, Gujarat, and is focused on making diagnostic testing more accessible across hospitals, clinics and community healthcare settings.
Problem
Routine health measurements are often captured manually, fragmented across systems or not interpreted quickly enough to support timely clinical decisions. Conventional diagnostic equipment can also be expensive, bulky or dependent on laboratory infrastructure. Scanbo aims to bridge these gaps through portable diagnostics, connected patient data and AI-powered analysis at the point of care.
Product
Scanbo's D-Series devices, including the D8, combine multiple vital-sign measurements with blood glucose testing in a portable system. Its HridayTaal cardiac AI agent analyses single-lead ECG waveforms to identify potential rhythm abnormalities and other cardiac indicators. The wider platform connects diagnostic data, clinical workflows and digital systems to help healthcare professionals make informed decisions.
Proof
Scanbo reported CDSCO approvals for the D8 diagnostic device and HridayTaal cardiac AI agent. The company's website reports more than seven million vital tests completed, over one million ECG AI analyses and deployments across 650-plus clinical settings.
People
Scanbo was founded by Ashissh Raichura, who serves as CEO, with Arvind Rajan as co-founder and a leader in Asia operations. The company combines expertise in hardware engineering, embedded systems, software, AI and medical-device manufacturing to develop integrated diagnostic technologies.
Purse
The company reports a $1.5 million Mitacs Canada grant supporting innovation, while its commercial model includes medical-device hardware, software subscriptions and AI licensing.
Plan
Scanbo is preparing to expand into North American markets, with US FDA 510(k) clearance targeted for Q1 2027 and Health Canada review underway. It is also developing additional cardiac AI capabilities and strengthening in-house manufacturing to support international growth.
Why it matters:
Scanbo is working to bring diagnostics and AI-assisted clinical interpretation closer to patients. By combining portable devices, connected health data and automated analysis, the company aims to help healthcare providers improve access to timely diagnostic insights, particularly in settings with limited resources.
FAST FACTS
|
Category
|
Details
|
|
Company
|
Scanbo India Private Limited
|
|
Founded
|
2019 (company incorporated in India)
|
|
Industry
|
HealthTech, MedTech, AI diagnostics
|
|
Founder & CEO
|
Ashissh Raichura
|
|
Co-founder
|
Arvind Rajan
|
|
Manufacturing and R&D
|
Surat, Gujarat
|
|
Global operations
|
India, Canada and the US
|
|
Lead device
|
Scanbo D8, part of the D-Series
|
|
AI platform
|
HridayTaal cardiac AI agent
|
|
Regulatory milestone
|
CDSCO approvals reported for D8 and HridayTaal
|
|
Funding
|
Total funding undisclosed; $1.5 million Mitacs Canada grant reported
|
|
Reach
|
650+ clinical settings; 7 million+ vital tests completed
|
|
Next
|
North American expansion, further cardiac AI development and manufacturing scale-up
|
Disclaimer: This profile is independent editorial content based on publicly available information and company disclosures reviewed as of October 2026. The profile does not constitute medical, clinical or investment advice.
